Meconium staining of amniotic fluid (MSAF) occurs in 10% to 15% of all deliveries. Infants born with MSAF are 100-fold more likely to develop substantial respiratory distress than infants born through clear amniotic fluid. About 1.5% to 8.0% of infants born through MSAF develop meconium aspiration syndrome (MAS).
1,2 Approximately 30% to 50% of infants with MAS have severe MAS, defined as the need for mechanical ventilation (MV).
3-5 The optimum methods of providing respiratory support to infants with MAS are not known.
6,7 Though ventilation is a life-saving measure, ventilation in itself results in ventilation-induced lung injury, and the need for MV translates into prolonged hospital stays, increased burden on the health care system, and increased treatment costs.
8,9 Nasal continuous positive airway pressure (NCPAP) as a primary respiratory therapy in MAS has not been studied extensively. When NCPAP is applied in newborns with MAS, it may resolve atelectasis by expanding partially obstructed small airways and stabilizing the collapsing terminal airways to enhance oxygen exchange. Nasal continuous positive airway pressure in MAS may be used as a substitute or as a bridge to MV. Therefore, we conducted this multicenter randomized clinical trial to evaluate the efficacy of NCPAP in comparison with standard care (5-10 L/min hood oxygen) in reducing the subsequent need for MV in newborns with MAS.